Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Observational 2Interventional 1

Sponsor

Conditions

COVID-19 3Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

Surveys and Questionnaires 6Standard of Care 6Blood Specimen Collection 6BNT162 Vaccine 5Hydroxychloroquine 4Surgical Procedures, Operative 3Specimen Handling 3Practice Guidelines as Topic 3COVID-19 Vaccines 32019-nCoV Vaccine mRNA-1273 3tocilizumab 2sotrovimab 2Pandemic Preparedness 2CVnCoV COVID-19 vaccine 2Azithromycin 2sinovac COVID-19 vaccine 1selinexor 1remdesivir 1ogalvibart 1monalizumab 1lenzilumab 1heterologous prime boost COVID-19 vaccination 1crexavibart 1cilgavimab and tixagevimab drug combination 1ciclesonide 1avdoralimab 1XAV-19 1Therapeutics 1Telemedicine 1Sperm Count 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × COVID-19 × 2019-nCoV Vaccine mRNA-1273 × Clear all
NCT05075538 2024-01-17

I-SPARC

Jules Bordet Institute

Phase 4 Terminated
152 enrolled

COVID-19, Neoplasms

NCT04930055 2023-05-19

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

Indiana University

Terminated
2,206 enrolled

COVID-19, Neoplasms

NCT05054218 2023-04-14

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

H. Lee Moffitt Cancer Center and Research Institute

Completed
336 enrolled

COVID-19

Data powered by HemOnc (CC BY 4.0) Colophon âš¡